Carlsmed (NASDAQ:CARL) Stock: Insider Jeffrey Bertolini Sells 747 Shares

Carlsmed, Inc. (NASDAQ:CARL) COO Jeffrey Bertolini sold 747 shares of the company’s stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $15.15, for a total transaction of $11,317.05. Following the completion of the sale, the chief operating officer directly owned 22,489 shares in the company, valued at $340,708.35. This trade represents a 3.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Jeffrey Bertolini also recently made the following trade(s):

• On Friday, October 30th, Jeffrey Bertolini sold 243 shares of Carlsmed stock. The shares were sold at an average price of $15.80, for a total transaction of $3,839.40.
• On Monday, October 5th, Jeffrey Bertolini sold 747 shares of Carlsmed stock. The stock was sold at an average price of $14.39, for a total transaction of $10,749.33.
• On Wednesday, September 30th, Jeffrey Bertolini sold 243 shares of Carlsmed stock. The stock was sold at an average price of $13.99, for a total value of $3,399.57.

Carlsmed Stock Performance

CARL stock opened at $15.32 on Friday. Carlsmed, Inc. has a 1 year low of $8.50 and a 1 year high of $17.23. The company has a quick ratio of 8.66, a current ratio of 8.84 and a debt-to-equity ratio of 0.18. The stock’s 50 day moving average price is $14.96 and its 200 day moving average price is $12.48.

Carlsmed (NASDAQ:CARL) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. Carlsmed had a negative return on equity of 38.06% and a negative net margin of 57.42%. The company had revenue of $18.94 million during the quarter. As a group, research analysts forecast that Carlsmed, Inc. will post -1.50 EPS for the current fiscal year.

Hedge Funds Weigh In On Carlsmed

Several large investors have recently added to or reduced their stakes in CARL. Zevenbergen Capital Investments LLC increased its stake in shares of Carlsmed by 50.4% during the 3rd quarter. Zevenbergen Capital Investments LLC now owns 17,900 shares of the company’s stock valued at $252,000 after acquiring an additional 6,000 shares during the last quarter. Bank of America Corp DE acquired a new stake in shares of Carlsmed in the second quarter worth approximately $108,000. Jupiter Topco LLC purchased a new stake in Carlsmed in the second quarter valued at approximately $12,992,000. Parkman Healthcare Partners LLC purchased a new stake in Carlsmed in the second quarter valued at approximately $6,200,000. Finally, Alpine Woods Capital Investors LLC purchased a new stake in Carlsmed in the second quarter valued at approximately $161,000.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Weiss Ratings raised shares of Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Truist Financial upped their target price on shares of Carlsmed from $18.00 to $20.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Wall Street Zen raised shares of Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, BTIG Research lifted their price target on shares of Carlsmed from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.50.

About Carlsmed

Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company combines patient-specific planning, advanced imaging, software and additive manufacturing to develop implants designed to address the anatomical needs of individual patients.

Its products include the aprevo® patient-specific interbody implant system, which is designed for use in spinal fusion procedures. Carlsmed’s technology is intended to support surgeons in planning procedures and selecting or creating implants that may help restore spinal alignment and improve surgical precision.

Carlsmed serves the spine-care market through relationships with spine surgeons, hospitals and other healthcare providers.